Coronavirus: Adar Poonawalla's Serum Institute of India makes Covishield vaccine

The gap between two Covishield doses has been increased to 12 to 16 weeks from the current six-eight weeks, the government said today, accepting the recommendation of experts. Increasing the gap is a good scientific decision, said Adar Poonawalla, the CEO of the Serum Institute of India (SSI) that makes Covishield.

"This is beneficial both from the efficacy and the immunogenicity standpoint. This is a very good move because this is based on data that the government received on the basis of which they made a good scientific decision to increase the gap," Adar Poonawalla told NDTV.

Several states are reporting a shortage of vaccines and the new rule is expected to not just ease the pressure off Covishield but also free up doses for a larger number of people to get their first dose of the vaccine.

In the early stages of vaccinations, the recommended interval between two doses was four to six weeks. That was increased to six to eight later but the government had said delaying the shot beyond the eighth week would weaken its effect.

According to a recent study, vaccine efficacy was significantly higher at 81.3 per cent (60.3-91.2) after two standard doses given at an interval of 12 weeks or longer, compared to 55.1 per cent (33-69.9) when given less than six weeks apart.

No change has been suggested for the gap between Covaxin doses.

The longer interval immunization strategy was recommended to the government by the National Technical Advisory Group on Immunisation.

"Based on the available real life evidence particularly from the UK, the COVID-19 working group agreed to increase the dosing interval to 12-16 weeks between two doses of Covishield vaccine," said unnamed sources quoted by Press Trust of India.